N/A N=10 Feasibility Study for Intrathoracic Nerve Stimulation
Postoperative Pain
Primary: Pain as Measured by the Visual-analog Scale — 1 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=144 HW006 LATERAL Thoracotomy
Left Sided Heart Failure
Primary: Subject is Alive on Original Device, Transplanted, or Explanted for Recovery at 6 Months — 128 Participants — p=0.0003
N/A N=304 Physician-Sponsored IDE for the Talent Endoluminal Stent Graft System for the Treatment of Thoracic Lesions
Thoracic Aortic Aneurysms · Thoracic Transections · Intramural Hematoma
Primary: Number of Participants With Successful Endoluminal Treatment of Thoracic Lesion — 294 Participants
N/A N=251 Efficacy of Post-operative Antibiotic Prophylaxis for Thoracic Surgery Requiring Tube Thoracostomy
Antibiotic Prophylaxis
Primary: Number of Participants Who Experienced At Least One Postoperative Infectious Complication — 13; 8 Participants — p=.26
Phase 4 N=102 Study of Exparel Versus Epidural for Pain Control After Thoracotomy
Pain Following Thoracotomy Surgery
Primary: Pain Scores With Cough on First Postoperative Day — 6.1; 6.9 units on a scale — p=0.142
N/A N=75 Transesophageal Echocardiography (TEE): A Novel Technique for Spinal Cord Imaging
Spinal Cord · Epidural
Primary: Number of Thoracic Spinal Segments Successfully Visualized With TEE — 12; 10 Thoracic segments
N/A N=109 Prospective Evaluation of 14F Thal Tube vs 28 French Chest Tube for Hemothorax and Use of Maximum Barrier Precautions
Hemothorax · Hemopneumothorax; Traumatic · Empyema
Primary: Number of Participants With Retained Hemothorax Following Initial Chest Tube Placement Requiring Intervention — 51; 48 Number of Participants — p=0.036
Phase 2 N=23 GORE TAG® Thoracic Endoprosthesis - 45 mm for the Treatment of Aneurysms of the Descending Thoracic Aorta
Aortic Aneurysm, Thoracic
Primary: Freedom From Major Adverse Events and Major Device Events Through 1 Year Post-treatment — 11 Participants
N/A N=113 Improving Quality of Life After Thoracic Surgery Using Patient-Reported Outcomes
Thoracic Surgery
Primary: Quality of Life at 12 Months — 80.97; 84.02 units on a scale
Phase 2 N=176 Video-assisted Thoracoscopic Surgery - Exparel Study
Pain, Postoperative
Primary: Number of Subjects With Post-operative Opioid Usage — 42; 58 Participants
N/A N=37 Pleural Manometry for the Characterization of Spontaneous and Tension Pneumothorax
Pneumothorax · Tension Pneumothorax
Primary: Pleural Pressure (Ppl) Prior to Evacuation of Pleural Air — 7.44; -1.79 cmH2O
Phase 4 N=27 Intrathecal (IT) Baclofen Drug Distribution
Muscle Spasticity
Primary: Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Cerebral Origin — 8; 7; 3; 3 Participants
N/A N=39 Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer
Breast Cancer
Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants
N/A N=36 The Impacts of Pulmonary Rehabilitation Therapy on Patients After Thoracic Surgery
Lung Neoplasms
Primary: Discharge 2weeks Exercise Capacity — 408.61; 311.94 meter(M) — p=<0.05
N/A N=10 GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysm
Primary: Absence of the Following Procedural Safety Events: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood…
N/A N=51 Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic
Aneurysm
Primary: The Number of Subjects Free From a Major Device Event Through 1 Month Post-treatment — 50 participants — p=0.0024
N/A N=154 GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry
Aortic Aneurysm, Thoracic · Descending Thoracic Aortic Dissection · Aortic Diseases
Primary: Number of Subjects With All-cause Mortality (Long-term) — 31 Participants
Phase 3 N=91 Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial
Thoracic Diseases · Postoperative Pain · Opioid Use
Primary: Average Daily In-Hospital Use of Opioids — 40; 45 Oral Morphine Equivalent per Day
Phase 2 N=49 Smoking Cessation Intervention for Thoracic Patients
Lung Cancer
Primary: Determination of the Feasibility of a Cognitive Behavioral Smoking Cessation Intervention. — 17; 32 participants
N/A N=25 Transesophageal Echocardiography (TEE) to Guide and Confirm Epidural Catheters in Pediatric Patients
Epidural Space
Primary: Number of Participants With Successful Epidural Catheter Placement — 17; 3 Participants
Phase 3 N=100 To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Disease
Aneurysm, Dissecting · Aortic Aneurysm, Thoracic
Primary: Percentage of Participants With Technically Successful Implant — 99.0 percentage of participants
Phase 3 N=191 Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy
Posterolateral Thoracotomy · Postoperative Pain
Primary: Area Under the Curve (AUC) of Pain Intensity at Rest Through 72 Hours — 472.1; 459.0 score on a scale * hr — p=0.5598
N/A N=129 Reducing Pain and Disability After Breast Cancer Surgery
Breast Cancer · Chronic Pain
Primary: The Proportion of Individuals Reporting Chronic Postoperative Pain 12 Months Following Breast Cancer Surgery With Lymph Node Dissection. — 5; 4 Participants
N/A N=31 Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms
Aortic Aneurysm, Thoracic
Primary: Number of Participants With Successful Study Device Access — 31 Participants
Phase 2 N=100 Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma
Blunt Chest Wall Trauma · Rib Fracture · Sternal Fracture
Primary: Opioid Requirement at 24 Hours Post-randomization — 38; 202 morphine milligram equivalents
N/A N=10 Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysms
Primary: Freedom From Major Adverse Events (MAE) at Day 30 — 3; 4 Participants
Phase 4 N=5 Fibrinolytic Therapy Versus Medical Thoracoscopy
Pleural Diseases
Primary: Number of Hospital Days for Required to Treat Complicated Parapneumonic Effusions or Pleural Empyema. — 13; 18.5 days
N/A N=160 Valor II: The Valiant Thoracic Stent Graft System Clinical Study
Thoracic Aortic Aneurysm
Primary: Percentage of Participants That Did NOT Experience Aneurysm-Related Mortality (Post-market Primary Endpoint) — 94.8 Percentage of participants
Phase 4 N=65 Assessment of Intercostal Block Scheduling in Preventing Acute Surgical and Post-surgical Pain in Thoracoscopic Surgery
Chest Pain · Surgery
Primary: Analgesic Use — 33.35; 35.32 MG
N/A N=120 CompuFlo Thoracic Epidural Study
Thoracic Epidural Anesthesia
Primary: Number of Participants With Successful Thoracic Epidural Catheter Placement — 52; 58 Participants